Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend payment, reflecting the company’s financial performance and potential shareholder returns.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company is focused on providing innovative vaccine solutions to address public health challenges.
YTD Price Performance: 14.29%
Average Trading Volume: 1,234,804
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$10.96B
See more data about 6185 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue